Kangmei Pharmaceutical (600518.SH) released its semi-annual results, with a net profit attributable to the parent company of 16.9 million yuan, an increase of 7.24% year-on-year.

Zhitong Finance APP News, Kangmei Pharmaceutical (600518.SH) disclosed its 2025 interim report. During the reporting period, the company achieved a revenue of 2.577 billion yuan, a year-on-year increase of 4.17%; its net profit attributable to the parent company was 16.9 million yuan, a year-on-year increase of 7.24%; its non-recurring net profit was a loss of 3.62 million yuan; and its basic earnings per share was 0.001 yuan.